Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | STS | P08842 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL87450 | 0.84 | CA1 (0.83) | CA1CA2CA12CA7CA9 | |
| SCHEMBL12620672 | 0.83 | CA1 (0.63) | CA1CA2CA12CA7CA9 | |
| SCHEMBL27647420 | 0.82 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL30271267 | 0.82 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL27647572 | 0.82 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL29504635 | 0.82 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL7746905 | 0.82 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL27647500 | 0.82 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL21440358 | 0.82 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL27667917 | 0.82 | CA1 (0.79) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114014838-B | Compound and preparation method and application thereof | 山东师范大学 | 2024-03-19 | — | — | CN | disclosed |
| US-20170002011-A1 | BENZENE SULFONAMIDES AS CCR9 INHIBITORS | NORGINE B.V. (NL) | 2017-01-05 | — | — | US | disclosed |
| US-8987463-B2 | Methods of synthesizing factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130211094-A1 | METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8394964-B2 | Methods of synthesizing factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20110319627-A1 | METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-12-29 | — | — | US | disclosed |
| US-7816540-B2 | Carboxyl- or hydroxyl-substituted benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2225221-A2 | CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009080555-A2 | CARBOXYL- OR HYDROXYL- SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163552-A1 | CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-06-25 | — | — | US | disclosed |
| WO-2008121602-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-09 | — | — | WO | disclosed |
| US-6423689-B1 | Peptidyl calcium channel blockers | WARNER-LAMBERT COMPANY | 2002-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319627-A1 | METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS | F12, F9, F7 | CA1 666/4885CA2 347/4885CA12 262/4885 |
| US-20130211094-A1 | METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS | F12, F9, F7 | CA1 666/4885CA2 347/4885CA12 262/4885 |
| US-20170002011-A1 | BENZENE SULFONAMIDES AS CCR9 INHIBITORS | CCR9, CCR1, CCR4 | CA1 2923/4885CA2 1766/4885CA12 2327/4885 |
| US-20090163552-A1 | CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | NR1H4, GPBAR1, SLC10A1 | CA1 2644/4885CA2 715/4885CA12 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.